Company profile: Kynos Therapeutics
1.1 - Company Overview
Company description
- Provider of small-molecule KMO inhibitor therapeutics for inflammation, immunity, and metabolism. Offers KNS366, a Phase I KMO inhibitor designed to reduce elevated 3-HK to prevent tissue damage and immune dysregulation during inflammation, and a portfolio targeting acute and chronic inflammatory disorders, including acute kidney injury and acute pancreatitis.
Products and services
- KMO Inhibitor Development: Enzyme-targeted programs architected to create KMO inhibitors across key indications in inflammation, immunity, and metabolism for therapeutic intervention
- KMO Inhibitors: A portfolio of small‑molecule inhibitors targeting kynurenine 3‑monooxygenase for therapeutic use in acute and chronic inflammatory disorders, including acute kidney injury and acute pancreatitis
- KNS366: A Phase I KMO inhibitor that reduces elevated 3‑hydroxykynurenine to prevent tissue damage and immune system dysregulation during inflammation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Kynos Therapeutics
Forward Pharma
HQ: Denmark
Website
- Description: Provider of biotechnology focused on the immunomodulatory compound dimethyl fumarate and derivatives for pharmaceutical drug applications to treat immune disorders such as multiple sclerosis and psoriasis; founded in 2005 and headquartered in Copenhagen, Denmark.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Forward Pharma company profile →
Alpine Immune Sciences
HQ: United States
Website
- Description: Provider of protein-based immunotherapies for autoimmune and inflammatory diseases, using a proprietary directed evolution platform to engineer native immune proteins into multi-targeted therapeutics. Pipeline includes povetacicept (ALPN-303), a dual BAFF/APRIL antagonist, and acazicolcept (ALPN-101), a dual CD28/ICOS antagonist; conducts clinical trials on investigational therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alpine Immune Sciences company profile →
Galapagos
HQ: Belgium
Website
- Description: Provider of small molecule medicines and investigational therapies in immunology and oncology. Develops CAR-T cell therapies via a decentralized manufacturing network and advances GLPG5101 (Phase 1/2 for relapsed/refractory non-Hodgkin lymphoma). Conducts clinical trials to evaluate treatments and seek regulatory approval; Jyseleca (filgotinib) transferred to Alfasigma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Galapagos company profile →
Delinia
HQ: United States
Website
- Description: Provider of novel therapeutics for autoimmune and inflammatory diseases, with a lead program focused on a molecule that selectively potentiates and expands regulatory T cells (Tregs), the immune cells critical to maintaining self-tolerance and immune system homeostasis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delinia company profile →
Acelyrin
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, identifying, acquiring, and accelerating development and commercialization of candidates including Izokibep (IL-17A inhibitor for psoriatic arthritis and hidradenitis suppurativa), Lonigutamab (subcutaneous anti-IGF-1R for thyroid eye disease), and SLRN-517 (fully human monoclonal targeting c-KIT for chronic urticaria and other mast cell-driven diseases).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acelyrin company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Kynos Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Kynos Therapeutics
2.2 - Growth funds investing in similar companies to Kynos Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Kynos Therapeutics
4.2 - Public trading comparable groups for Kynos Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →